CLAIMS

1. Use of a pharmaceutical composition comprising

   a particulate biodegradable substrate coated or impregnated with a matrix composition comprising:

   (a) a biodegradable polymer;

   (b) at least one phospholipid having hydrocarbon chains of at least 12 carbons and

   (c) a taxane,

   for the preparation of a medicament for the treatment of a solid tumor.

2. The use of claim 1, wherein the solid tumor is selected from the group consisting of colon carcinoma, prostate cancer, pancreatic cancer, breast cancer, esophageal cancer, gastric cancer, Head & Neck cancer and soft tissue sarcomas.

3. The use of claim 1, wherein the solid tumor is a brain tumor selected from a primary brain tumor and a metastatic brain tumor.

4. The use of claim 1, wherein the brain tumor is a primary glioblastoma multiforme.

5. The use of claim 1, wherein the solid tumor is a chemotherapy resistant tumor.

6. The use of claim 1, wherein the solid tumor is resistant to docetaxel.

7. The use of any one of claims 1 to 6, wherein the pharmaceutical composition is to be administered to the inner surface of a tumor resection cavity; preferably wherein the pharmaceutical composition is to be administered to the inner surface of the solid tumor resection cavity at a dose ranging from 20 mg to 260 mg per surface area of 1 cm^2; or at a dose ranging from 50 mg to 120 mg per surface area of 1 cm^2; or at a dose ranging from 75 mg to 160 mg per surface area of 1 cm^2.

8. The use of any one of claims 1 to 7 wherein the taxane is selected from the group consisting of docetaxel, paclitaxel and cabazitaxel; preferably, wherein the taxane is docetaxel.

9. The use according to any one of claims 1 to 8, wherein the polymer is a polyester; preferably, wherein the polyester is selected from polylactic acid (PLA), polyglycolic acid (PGA) and poly (lactic-co-glycolic acid) (PLGA); preferably, wherein the polymer is PLGA; or

   wherein the phospholipid is a phosphatidylcholine selected from DMPC, DPPC, DSPC and DOPC; preferably, wherein the phosphatidylcholine is DMPC.

10. The use of any one of claim 1 to 9, wherein the particulate biodegradable substrate consists of particles having an average particle size of less than about 200 µm; or wherein the particle size of the biodegradable substrate is between about 50 and 150 µm; or wherein the particle size of the biodegradable substrate is between about 50 and 100 µm.
11. The use of any one of claim 1 to 10, wherein the particulate substrate consists of tri calcium phosphate.
12. The use of any one of claims 1 to 11, wherein the particulate biodegradable substrate constitutes between about 80 to 93% (w/w) of the total weight of the pharmaceutical composition; the polymer constitutes between about 0.5 – 5% (w/w) of the total weight of the pharmaceutical composition and the at least one phospholipid having hydrocarbon chains of at least 12 carbons constitutes between about 4.0 – 15% (w/w) of the total weight of the pharmaceutical composition .
13. The use of any one of claim 1 to 12, wherein the taxane constitutes up to 2.6% (w/w) of the total weight of the pharmaceutical composition; or wherein the taxane constitutes between about 0.5 to 1.5% (w/w) of the total weight of the pharmaceutical composition; or wherein the taxane constitutes between about 0.6 to 1.3% (w/w) of the total weight of the pharmaceutical composition.
14. The use of any one of claims 1 to 13, wherein the pharmaceutical composition further comprises cholesterol; preferably wherein the cholesterol constitutes up to 2% (w/w) of the total weight of the pharmaceutical composition; or
    wherein the cholesterol constitutes between about 0.8-1.5% (w/w) of the total weight of the pharmaceutical composition.
15. The use of any one of the preceding claims further comprising a pH adjustment agent; preferably, wherein the pH of the pharmaceutical composition is between 4.0 and 6.0.
16. The use according to any one of the preceding claims, wherein the taxane penetrates to a distance of at least 0.5 cm away from the surface of the resected tumor; or
    wherein the taxane penetrates to a distance of at least 1.0 cm away from the surface of the resected tumor; or
    wherein the taxane penetrates to a distance of at least 1.5 cm away from the surface of the resected tumor.

17. Use of a pharmaceutical composition comprising: (a) 80 - 93% (w/w) of β-tricalcium phosphate particles; (b) 1.0 – 4.0% (w/w) of PLGA; (c) 4.0 – 15.0% (w/w) DMPC, (d) 0 – 2.0% (w/w) of cholesterol and (d) 0.2 to 2.6% (w/w) of docetaxel, for the preparation of a medicament for the treatment of a brain tumor.
18. The use of any one of the preceding claims wherein the pharmaceutical composition is in the form selected from the group consisting of a powder, a paste and a suspension for injection.